Avesthagen Overview

  • Founded
  • 1998
Founded
  • Status
  • Private
  • Employees
  • 400
Employees
  • Latest Deal Type
  • PE Growth
  • Financing Rounds
  • 10
  • Investments
  • 3

Avesthagen General Information

Description

Operator of a life science firm intended to pioneer the convergence between food, pharma and population genetics. The company's integrated systems biology platform delivers preventive healthcare products and technologies by leveraging a multi-omics approach for certain degenerative diseases, conditions and disorders including diabetes, cardio-vascular diseases, osteoporosis, osteoarthritis and bone loss and the improvement of certain health functions, in order to provide healthy food for people and protect the environment for generations to come.

Contact Information

Formerly Known As
Avestha Gengraine Technologies
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Primary Office
  • 43/39, Level Four, 2nd Cross Promenade Road
  • Frazer Town
  • Bangalore, 560025
  • India
+91 080 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Avesthagen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Avesthagen‘s full profile, request access.

Request a free trial

Avesthagen Patents

Avesthagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20110204222-A1 Method of characterizing phytochemicals from trigonella foenum graceum Abandoned 28-Oct-2008 000000000
AU-2009309387-A1 An expression vector and processes thereof Abandoned 28-Oct-2008 000000000
AU-2009309408-A1 A method of characterizing phytochemicals from trigonella foenum graceum Abandoned 28-Oct-2008 000000000
EP-2417446-A1 A method of characterizing phytochemicals from trigonella foenum graceum Withdrawn 28-Oct-2008 000000000
EP-2417446-A4 A method of characterizing phytochemicals from trigonella foenum graceum Withdrawn 28-Oct-2008 A61K36/48
To view Avesthagen’s complete patent history, request access »

Avesthagen Executive Team (4)

Name Title Board Seat Contact Info
Parag Shah Chief Executive Officer
Villoo Patell Ph.D Founder, Chairman & Managing Director
Renuka Jain Senior Vice President & Chief Scientific Officer Bio-Nutrition and Metabolomics
You’re viewing 3 of 4 executive team members. Get the full list »

Avesthagen Board Members (4)

Name Representing Role Since
00000 000000 Avesthagen Board Member 000 0000
000000 00000 Avesthagen Board Member 000 0000
000000 000000 00.0 Avesthagen Founder, Chairman & Managing Director 000 0000
You’re viewing 3 of 4 board members. Get the full list »

Avesthagen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avesthagen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Avesthagen‘s full profile, request access.

Request a free trial

Avesthagen Investments (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 (0 18-Jul-2007 0000000000 0000 Other Pharmaceuticals and Biotechnology 000000 00
000000 0000 0 01-Apr-2005 0000000000 00.00 Food Products 000000 00
Avesta Biotherapeutics and Research 01-May-2004 Joint Venture Biotechnology 000000 00
To view Avesthagen’s complete investments history, request access »

Avesthagen Subsidiaries (1)

Company Name Industry Location Founded
000000 0000 00000 Food Products Bangalore, India 0000
To view Avesthagen’s complete subsidiaries history, request access »